SciHub
文献互助
期刊查询
一搜即达
科研导航
交流社区
登录
注册
发布
文献
求助
首页
我的求助
捐赠本站
已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!
novia
Lv5
1450 积分
2021-09-09 加入
最近求助
最近应助
互助留言
The CDK4/6 inhibitor revolution — a game-changing era for breast cancer treatment
1个月前
已完结
Burosumab: current status and future prospects
3个月前
已完结
Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial
3个月前
已完结
Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study
5个月前
已完结
First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer☆
5个月前
已完结
The global burden of lung cancer: current status and future trends
5个月前
已完结
Inhibitory Effect of PD-1/PD-L1 and Blockade Immunotherapy in Leukemia
7个月前
已完结
Available Systemic Treatments and Emerging Therapies for Breast Cancer Brain Metastases
8个月前
已完结
EZH1/2 as targets for cancer therapy
9个月前
已完结
EZH1/2 as targets for cancer therapy
10个月前
已完结
没有进行任何应助
感谢
5个月前
十分感谢
1年前
最近帖子
最近评论
没有发布任何帖子
没有发布任何评论